Telix Pharmaceuticals Limited (NASDAQ:TLX – Free Report) – Equities research analysts at HC Wainwright cut their FY2026 EPS estimates for shares of Telix Pharmaceuticals in a note issued to investors on Tuesday, July 28th. HC Wainwright analyst R. Burns now forecasts that the company will earn $0.07 per share for the year, down from their previous estimate of $0.15. HC Wainwright has a “Buy” rating and a $20.00 price objective on the stock. The consensus estimate for Telix Pharmaceuticals’ current full-year earnings is $0.06 per share.
A number of other equities analysts also recently issued reports on the stock. Wedbush reissued an “outperform” rating and issued a $22.00 price target on shares of Telix Pharmaceuticals in a research note on Monday, July 6th. Royal Bank Of Canada downgraded Telix Pharmaceuticals from an “outperform” rating to a “sector perform” rating in a report on Friday, July 17th. Weiss Ratings reissued a “sell (d)” rating on shares of Telix Pharmaceuticals in a research report on Friday, July 17th. Citigroup lowered their target price on Telix Pharmaceuticals from $22.50 to $22.00 and set a “buy” rating for the company in a research note on Tuesday, July 7th. Finally, Wall Street Zen upgraded Telix Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Saturday, April 11th. One investment analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Telix Pharmaceuticals presently has an average rating of “Moderate Buy” and an average price target of $20.40.
Telix Pharmaceuticals Stock Performance
Shares of TLX opened at $10.19 on Wednesday. The firm’s 50-day moving average price is $10.34 and its 200-day moving average price is $9.21. The company has a quick ratio of 1.27, a current ratio of 1.43 and a debt-to-equity ratio of 1.08. Telix Pharmaceuticals has a 1-year low of $6.28 and a 1-year high of $14.27.
Institutional Investors Weigh In On Telix Pharmaceuticals
A number of hedge funds and other institutional investors have recently bought and sold shares of TLX. Russell Investments Group Ltd. purchased a new position in shares of Telix Pharmaceuticals during the second quarter valued at approximately $975,000. Jane Street Group LLC purchased a new stake in shares of Telix Pharmaceuticals in the 2nd quarter worth approximately $564,000. IHT Wealth Management LLC bought a new position in Telix Pharmaceuticals during the 2nd quarter valued at approximately $213,000. Rhumbline Advisers raised its stake in Telix Pharmaceuticals by 117.3% during the third quarter. Rhumbline Advisers now owns 2,579 shares of the company’s stock valued at $25,000 after buying an additional 1,392 shares during the last quarter. Finally, JPMorgan Chase & Co. purchased a new position in Telix Pharmaceuticals during the third quarter valued at $243,000.
Telix Pharmaceuticals Company Profile
Telix Pharmaceuticals (NASDAQ: TLX) is a clinical-stage biopharmaceutical company focused on the development and commercialization of molecularly targeted radiopharmaceuticals for the diagnosis and treatment of cancer. Leveraging expertise in radiochemistry, nuclear medicine and oncology, Telix aims to address unmet clinical needs across a range of tumor types by pairing diagnostic imaging agents with therapeutic radionuclides.
The company’s pipeline spans both imaging and therapeutic candidates.
Featured Stories
- Five stocks we like better than Telix Pharmaceuticals
- These 3 Stocks Have Soared in 2026—Can They Keep Climbing?
- Hasbro’s Earnings Beat Shows Why This Is No Longer Just a Toy Story
- Rambus: Another AI Phoenix Ready to Rise From the Ashes of Correction
- Chips & Clips: Memory Tariffs Rewire Tech Supply Chains
Receive News & Ratings for Telix Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Telix Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
